Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo

Antibody-based delivery of bioactive molecules represents a promising strategy for the improvement of cancer immunotherapy. Here, we describe the generation and characterization of R6N, a novel fully human antibody specific to the alternatively spliced domain D of Tenascin C, which is highly express...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadal, Lisa, Corbellari, Riccardo, Villa, Alessandra, Weiss, Tobias, Weller, Michael, Neri, Dario, De Luca, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646483/
https://www.ncbi.nlm.nih.gov/pubmed/33136526
http://dx.doi.org/10.1080/19420862.2020.1836713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646483/
https://www.ncbi.nlm.nih.gov/pubmed/33136526
http://dx.doi.org/10.1080/19420862.2020.1836713

Ejemplares similares